Ok_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":879584405,"tweetId":"879584405","gmtCreate":1636738936047,"gmtModify":1636738936194,"author":{"id":3549455086460474,"idStr":"3549455086460474","authorId":3549455086460474,"authorIdStr":"3549455086460474","name":"RocketToMars","avatar":"https://static.tigerbbs.com/e454fc8aa9e282f1caae6fe919b0b36e","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":15,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/879584405","repostId":1152324783,"repostType":4,"repost":{"id":"1152324783","kind":"news","pubTimestamp":1636724821,"share":"https://www.laohu8.com/m/news/1152324783?lang=&edition=full","pubTime":"2021-11-12 21:47","market":"us","language":"en","title":"Why Are Biogen Shares Gaining Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152324783","media":"Benzinga","summary":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's dise","content":"<ul>\n <li><b>Biogen Inc</b>&nbsp;and&nbsp;<b>Eisai Co Ltd</b>&nbsp;have&nbsp;new data released&nbsp;for Aduhelm (aducanumab-avwa) in Alzheimer's disease.</li>\n <li>The analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.</li>\n <li>According to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.</li>\n <li>Biogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.</li>\n <li>The Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.</li>\n <li>In one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.</li>\n <li>In the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.</li>\n <li><b>Price Action:</b>&nbsp;BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Are Biogen Shares Gaining Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Are Biogen Shares Gaining Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24057338/why-are-biogen-shares-gaining-today","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152324783","content_text":"Biogen Inc and Eisai Co Ltd have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease.\nThe analysis comes from approximately 7,000 plasma samples from more than 1,800 patients in Phase 3 trials.\nAccording to new data released, Aduhelm lowers levels of a second protein that accumulates in the brains of people with the disease.\nBiogen said its Phase 3 studies found that Aduhelm significantly lowered blood levels of an abnormal form of the protein tau - another target of experimental Alzheimer's drugs.\nThe Company said that the tau levels were correlated to changes in amyloid plaques and slowed the cognitive and functional decline.\nIn one trial, tau levels in patients with early Alzheimer's given the highest dose of Aduhelm fell 13%, compared with an increase of 8% for placebo patients.\nIn the second trial, high-dose patients saw tau levels decrease 16%, while levels in the placebo group rose 9%.\nPrice Action: BIIB shares are up 3.54% at $276 during the premarket session on the last check Friday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":487,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/879584405"}